journal article·2020-04-28Open access

Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2

Yanxiao Han, Petr Král

ACS Nano· Volume 14· Issue 4

Abstract

Peptide inhibitors against the SARS-CoV-2 coronavirus, currently causing a worldwide pandemic, are designed and simulated. The inhibitors are mostly formed by two sequential self-supporting α-helices (bundle) extracted from the protease domain (PD) of angiotensin-converting enzyme 2 (ACE2), which bind to the SARS-CoV-2 receptor binding domains. Molecular dynamics simulations revealed that the α-helical peptides maintain their secondary structure and provide a highly specific and stable binding (blocking) to SARS-CoV-2. To provide a multivalent binding to the SARS-CoV-2 receptors, many such peptides could be attached to the surfaces of nanoparticle carriers. The proposed peptide inhibitors could provide simple and efficient therapeutics against the COVID-19 disease.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: SARS-CoV-2 and COVID-19 Research · Computational Drug Discovery Methods · Lipid Membrane Structure and Behavior

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry, University of Illinois at Chicago, Chicago, Illinois 60607, United States

Department of Physics, Biopharmaceutical Sciences, and Chemical Engineering, University of Illinois at Chicago, Chicago, Illinois 60607, United States

Funding

University of Illinois at Chicago

References (21)

Show source-provided references
1. 10.1038/s41564-020-0695-z10.1038/s41564-020-0695-z ↗
2. 10.1016/S0140-6736(20)30211-710.1016/S0140-6736(20)30211-7 ↗
3. 10.1016/S0140-6736(20)30183-510.1016/S0140-6736(20)30183-5 ↗
4. 10.1038/s41586-020-2012-710.1038/s41586-020-2012-7 ↗
5. 10.1126/science.abb250710.1126/science.abb2507 ↗
6. 10.1146/annurev-virology-110615-04230110.1146/annurev-virology-110615-042301 ↗
7. 10.1128/JVI.77.16.8801-8811.200310.1128/JVI.77.16.8801-8811.2003 ↗
8. 10.1128/JVI.00127-2010.1128/JVI.00127-20 ↗
9. 10.1126/science.abb276210.1126/science.abb2762 ↗
10. 10.1016/j.apsb.2020.02.00810.1016/j.apsb.2020.02.008 ↗
11. Wang J. · ChemRxix
12. 10.1016/j.ab.2004.10.00310.1016/j.ab.2004.10.003 ↗
13. 10.1016/j.compbiolchem.2007.02.00610.1016/j.compbiolchem.2007.02.006 ↗
14. 10.1038/nmat505310.1038/nmat5053 ↗
15. 10.1126/sciadv.aax931810.1126/sciadv.aax9318 ↗
16. 10.1039/C8CS00022K10.1039/C8CS00022K ↗
17. 10.1038/nrd239910.1038/nrd2399 ↗
18. 10.1080/17425247.2018.150325110.1080/17425247.2018.1503251 ↗
19. 10.1002/jcc.2028910.1002/jcc.20289 ↗
20. 10.1021/jp973084f10.1021/jp973084f ↗
21. 10.1063/1.46439710.1063/1.464397 ↗